[go: up one dir, main page]

MX2009010207A - Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c. - Google Patents

Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.

Info

Publication number
MX2009010207A
MX2009010207A MX2009010207A MX2009010207A MX2009010207A MX 2009010207 A MX2009010207 A MX 2009010207A MX 2009010207 A MX2009010207 A MX 2009010207A MX 2009010207 A MX2009010207 A MX 2009010207A MX 2009010207 A MX2009010207 A MX 2009010207A
Authority
MX
Mexico
Prior art keywords
hcv
hydrazido
protease
peptides
inhibitors
Prior art date
Application number
MX2009010207A
Other languages
English (en)
Inventor
Srikanth Venkatraman
Neng-Yang Shih
George F Njoroge
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009010207A publication Critical patent/MX2009010207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe compuestos novedosos, que tienen actividad inhibidora de proteasa de HCV así como métodos para preparar dichos compuestos; en otra modalidad, la invención describe composiciones farmacéuticas que comprenden los compuestos así como métodos para usarlos para tratar trastornos asociados con la proteasa de HCV.
MX2009010207A 2007-03-23 2008-03-20 Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c. MX2009010207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91973207P 2007-03-23 2007-03-23
PCT/US2008/003654 WO2008118332A2 (en) 2007-03-23 2008-03-20 Hydrazido-peptides as inhibitors of hcv ns3-protease

Publications (1)

Publication Number Publication Date
MX2009010207A true MX2009010207A (es) 2009-10-19

Family

ID=39789182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010207A MX2009010207A (es) 2007-03-23 2008-03-20 Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.

Country Status (7)

Country Link
US (1) US20100104534A1 (es)
EP (1) EP2139911A2 (es)
JP (1) JP2010522174A (es)
CN (1) CN101679483A (es)
CA (1) CA2681598A1 (es)
MX (1) MX2009010207A (es)
WO (1) WO2008118332A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5486928B2 (ja) 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
EP2183229B1 (en) 2007-07-26 2012-04-18 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
JP5451752B2 (ja) 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
DK2324018T3 (da) 2008-07-25 2013-10-14 Boehringer Ingelheim Int Cykliske inhibitorer af 11 beta-hydroxysteroid dehydrogenase 1
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
WO2022020711A1 (en) * 2020-07-24 2022-01-27 The Texas A&M University System Sars-cov-2 main protease inhibitors
CN114989045B (zh) * 2022-06-14 2023-09-08 斯坦德药典标准物质研发(湖北)有限公司 合成奈玛特韦的中间体及其制法以及合成奈玛特韦的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757072B2 (en) * 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6624290B2 (en) * 2000-02-08 2003-09-23 Schering Corporation Azapeptides useful in the treatment of Hepatitis C
CA2552319C (en) * 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
JP4874227B2 (ja) * 2004-02-27 2012-02-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド
MX2007002371A (es) * 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.

Also Published As

Publication number Publication date
US20100104534A1 (en) 2010-04-29
WO2008118332A2 (en) 2008-10-02
CN101679483A (zh) 2010-03-24
JP2010522174A (ja) 2010-07-01
CA2681598A1 (en) 2008-10-02
EP2139911A2 (en) 2010-01-06
WO2008118332A3 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
TW200938526A (en) Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
CA2871471C (en) Dna-pk inhibitors
MY148253A (en) Azaadamantane derivatives and methods of use
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2010021717A3 (en) Hcv protease inhibitors
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal